Barclays PLC Biomarin Pharmaceutical Inc Call Options Transaction History

Barclays PLC

$377 Billion
Q3 2024

Call Options

19 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 15, 2024	SELL	$69.02 - $93.84 $2.74 Million - $3.73 Million	-39,700 Reduced 63.83%	22,500 $1.58 Million
Q2 2024 Aug 14, 2024	BUY	$74.43 - $92.22 $4.63 Million - $5.74 Million	62,200 New	62,200 $5.12 Million
Q4 2023 Feb 15, 2024	BUY	$76.22 - $98.51 $2.29 Million - $2.96 Million	30,000 New	30,000 $2.89 Million
Q2 2021 Aug 13, 2021	BUY	$75.51 - $84.79 $739,998 - $830,942	9,800 Added 84.48%	21,400 $1.79 Million
Q1 2021 May 13, 2021	SELL	$74.73 - $90.69 $986,436 - $1.2 Million	-13,200 Reduced 53.23%	11,600 $876,000
Q4 2020 Feb 11, 2021	BUY	$72.61 - $90.2 $1.45 Million - $1.8 Million	20,000 Added 416.67%	24,800 $2.18 Million
Q3 2020 Nov 12, 2020	SELL	$71.87 - $131.03 $8.16 Million - $14.9 Million	-113,500 Reduced 95.94%	4,800 $365,000
Q2 2020 Aug 12, 2020	BUY	$79.55 - $124.22 $5.74 Million - $8.97 Million	72,200 Added 156.62%	118,300 $14.6 Million
Q1 2020 May 13, 2020	BUY	$71.37 - $96.85 $1.21 Million - $1.65 Million	17,000 Added 58.42%	46,100 $3.9 Million
Q4 2019 Feb 10, 2020	SELL	$64.27 - $86.37 $1.18 Million - $1.58 Million	-18,300 Reduced 38.61%	29,100 $2.46 Million
Q3 2019 Nov 14, 2019	BUY	$67.4 - $85.11 $1.61 Million - $2.03 Million	23,900 Added 101.7%	47,400 $3.2 Million
Q2 2019 Aug 14, 2019	SELL	$80.35 - $93.9 $96,420 - $112,680	-1,200 Reduced 4.86%	23,500 $2.01 Million
Q1 2019 May 15, 2019	SELL	$84.2 - $98.62 $5.28 Million - $6.18 Million	-62,700 Reduced 71.74%	24,700 $2.19 Million
Q4 2018 Feb 14, 2019	SELL	$80.14 - $106.07 $4.75 Million - $6.29 Million	-59,300 Reduced 40.42%	87,400 $7.44 Million
Q3 2018 Nov 14, 2018	SELL	$93.92 - $105.72 $1.26 Million - $1.42 Million	-13,400 Reduced 8.37%	146,700 $14.2 Million
Q2 2018 Aug 14, 2018	BUY	$76.01 - $99.03 $3.38 Million - $4.41 Million	44,500 Added 38.49%	160,100 $15.1 Million
Q1 2018 May 15, 2018	SELL	$77.67 - $92.63 $4.16 Million - $4.96 Million	-53,500 Reduced 31.64%	115,600 $9.37 Million
Q4 2017 Feb 14, 2018	BUY	$80.76 - $95.13 $8.63 Million - $10.2 Million	106,900 Added 171.86%	169,100 $15.1 Million
Q3 2017 Nov 14, 2017	BUY	$80.6 - $94.95 $5.01 Million - $5.91 Million	62,200	62,200 $5.79 Million

Others Institutions Holding BMRN

# of Institutions

635

Shares Held

178M

Call Options Held

2.01M

Put Options Held

1.28M

Black Rock Inc. New York, NY

22.7M
Shares

$1.44 Billion
0.04% of portfolio
Vanguard Group Inc Valley Forge, PA

19.3M
Shares

$1.22 Billion
0.02% of portfolio
Primecap Management CO Pasadena, CA

18.9M
Shares

$1.2 Billion
0.99% of portfolio
Dodge & Cox San Francisco, CA

13.9M
Shares

$881 Million
0.59% of portfolio
Capital Research Global Investors Los Angeles, CA

10.5M
Shares

$666 Million
0.16% of portfolio

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $11.8B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account